| pubmed-article:17910629 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17910629 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:17910629 | lifeskim:mentions | umls-concept:C0006826 | lld:lifeskim |
| pubmed-article:17910629 | lifeskim:mentions | umls-concept:C0035648 | lld:lifeskim |
| pubmed-article:17910629 | lifeskim:mentions | umls-concept:C0023434 | lld:lifeskim |
| pubmed-article:17910629 | lifeskim:mentions | umls-concept:C1527148 | lld:lifeskim |
| pubmed-article:17910629 | lifeskim:mentions | umls-concept:C1518071 | lld:lifeskim |
| pubmed-article:17910629 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:17910629 | pubmed:dateCreated | 2007-10-3 | lld:pubmed |
| pubmed-article:17910629 | pubmed:abstractText | Previous studies suggested that patients with chronic lymphocytic leukaemia (CLL) are at a three- to fivefold increased risk of developing a second lymphoproliferative disorder (LPD). This observational cohort study used the Mayo Clinic CLL Database to identify factors associated with developing a second LPD. A second LPD was identified in 26 (2.7%) of 962 CLL patients during a median follow-up of 3.3 years. Diffuse large B-cell lymphoma was the most common subtype of secondary LPD (12 of 26 cases). Patients previously treated for CLL had a trend toward higher prevalence of second LPD (4%) compared with previously untreated patients (2%; P = 0.053). More strikingly, patients treated with purine nucleoside analogues (PNA) had a significantly increased risk of subsequent second LPD (5.2%) compared with patients who had not received PNA (1.9%; P = 0.008). No statistically significant association was observed between risk of second LPD and other CLL characteristics (ZAP-70, CD38, IgV(H) mutation status or cytogenetic abnormalities). In this series, prior treatments with PNA or anthracyclines were the only significant factors associated with risk of developing a second LPD in patients with CLL. Physicians should strictly adhere to established criteria to initiate treatment for CLL patients who are not participating in clinical trials. | lld:pubmed |
| pubmed-article:17910629 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17910629 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17910629 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17910629 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17910629 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17910629 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17910629 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17910629 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17910629 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17910629 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17910629 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17910629 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:17910629 | pubmed:issn | 0007-1048 | lld:pubmed |
| pubmed-article:17910629 | pubmed:author | pubmed-author:JelinekDiane... | lld:pubmed |
| pubmed-article:17910629 | pubmed:author | pubmed-author:HabermannThom... | lld:pubmed |
| pubmed-article:17910629 | pubmed:author | pubmed-author:HoyerJames... | lld:pubmed |
| pubmed-article:17910629 | pubmed:author | pubmed-author:KayNeil ENE | lld:pubmed |
| pubmed-article:17910629 | pubmed:author | pubmed-author:ShanafeltTait... | lld:pubmed |
| pubmed-article:17910629 | pubmed:author | pubmed-author:SlagerSusan... | lld:pubmed |
| pubmed-article:17910629 | pubmed:author | pubmed-author:CallTimothy... | lld:pubmed |
| pubmed-article:17910629 | pubmed:author | pubmed-author:ZentClive SCS | lld:pubmed |
| pubmed-article:17910629 | pubmed:author | pubmed-author:SchwagerSusan... | lld:pubmed |
| pubmed-article:17910629 | pubmed:author | pubmed-author:ReinaldaMegan... | lld:pubmed |
| pubmed-article:17910629 | pubmed:author | pubmed-author:Maddocks-Chri... | lld:pubmed |
| pubmed-article:17910629 | pubmed:author | pubmed-author:BowenDeborah... | lld:pubmed |
| pubmed-article:17910629 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17910629 | pubmed:volume | 139 | lld:pubmed |
| pubmed-article:17910629 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17910629 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17910629 | pubmed:pagination | 398-404 | lld:pubmed |
| pubmed-article:17910629 | pubmed:meshHeading | pubmed-meshheading:17910629... | lld:pubmed |
| pubmed-article:17910629 | pubmed:meshHeading | pubmed-meshheading:17910629... | lld:pubmed |
| pubmed-article:17910629 | pubmed:meshHeading | pubmed-meshheading:17910629... | lld:pubmed |
| pubmed-article:17910629 | pubmed:meshHeading | pubmed-meshheading:17910629... | lld:pubmed |
| pubmed-article:17910629 | pubmed:meshHeading | pubmed-meshheading:17910629... | lld:pubmed |
| pubmed-article:17910629 | pubmed:meshHeading | pubmed-meshheading:17910629... | lld:pubmed |
| pubmed-article:17910629 | pubmed:meshHeading | pubmed-meshheading:17910629... | lld:pubmed |
| pubmed-article:17910629 | pubmed:meshHeading | pubmed-meshheading:17910629... | lld:pubmed |
| pubmed-article:17910629 | pubmed:meshHeading | pubmed-meshheading:17910629... | lld:pubmed |
| pubmed-article:17910629 | pubmed:meshHeading | pubmed-meshheading:17910629... | lld:pubmed |
| pubmed-article:17910629 | pubmed:meshHeading | pubmed-meshheading:17910629... | lld:pubmed |
| pubmed-article:17910629 | pubmed:meshHeading | pubmed-meshheading:17910629... | lld:pubmed |
| pubmed-article:17910629 | pubmed:meshHeading | pubmed-meshheading:17910629... | lld:pubmed |
| pubmed-article:17910629 | pubmed:meshHeading | pubmed-meshheading:17910629... | lld:pubmed |
| pubmed-article:17910629 | pubmed:meshHeading | pubmed-meshheading:17910629... | lld:pubmed |
| pubmed-article:17910629 | pubmed:meshHeading | pubmed-meshheading:17910629... | lld:pubmed |
| pubmed-article:17910629 | pubmed:meshHeading | pubmed-meshheading:17910629... | lld:pubmed |
| pubmed-article:17910629 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17910629 | pubmed:articleTitle | Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia. | lld:pubmed |
| pubmed-article:17910629 | pubmed:affiliation | Mayo Clinic College of Medicine, Rochester, MN 55905, USA. | lld:pubmed |
| pubmed-article:17910629 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17910629 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:17910629 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17910629 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17910629 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17910629 | lld:pubmed |
